TNSN01076A1 - Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant - Google Patents
Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenantInfo
- Publication number
- TNSN01076A1 TNSN01076A1 TNTNSN01076A TNSN01076A TNSN01076A1 TN SN01076 A1 TNSN01076 A1 TN SN01076A1 TN TNSN01076 A TNTNSN01076 A TN TNSN01076A TN SN01076 A TNSN01076 A TN SN01076A TN SN01076 A1 TNSN01076 A1 TN SN01076A1
- Authority
- TN
- Tunisia
- Prior art keywords
- growth hormone
- antidepressants
- associations
- compositions containing
- hormone secretagogues
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000935 antidepressant agent Substances 0.000 title abstract 2
- 229940005513 antidepressants Drugs 0.000 title abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 title abstract 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'INVENTION CONCERNE UNE ASSOCIATION COMPRENANT UN SECRETAGOGUE D'HORMONE DE CROISSANCE ET UN ANTIDEPRESSEUR. ELLE CONCERNE EGALEMENT UNE COMPOSITION COMPRENANT UNE TELLE ASSOCIATION ET UN SUPPORT, VEHICULE OU DILUANT PHARMACEUTIQUEMENT ACCEPTABLE. APPLICATION : UTILISATION DE CETTE ASSOCIATION OU COMPOSITION POUR LE TRAITEMENT DE DIVERSES AFFECTIONS DE PATIENTS SUBISSANT UNE INTERVENTION MEDICALE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20701700P | 2000-05-25 | 2000-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN01076A1 true TNSN01076A1 (fr) | 2005-11-10 |
Family
ID=22768871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN01076A TNSN01076A1 (fr) | 2000-05-25 | 2001-05-24 | Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant |
Country Status (17)
Country | Link |
---|---|
US (1) | US20020002137A1 (fr) |
EP (1) | EP1284753A2 (fr) |
JP (1) | JP2003534294A (fr) |
AR (1) | AR028620A1 (fr) |
AU (1) | AU2001255013A1 (fr) |
BR (1) | BR0111002A (fr) |
CA (1) | CA2408036A1 (fr) |
DO (1) | DOP2001000154A (fr) |
EC (1) | ECSP014082A (fr) |
GT (1) | GT200100089A (fr) |
MX (1) | MXPA02011554A (fr) |
PA (1) | PA8517701A1 (fr) |
PE (1) | PE20011262A1 (fr) |
SV (1) | SV2001000465A (fr) |
TN (1) | TNSN01076A1 (fr) |
UY (1) | UY26731A1 (fr) |
WO (1) | WO2001089570A2 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
EP1661898A4 (fr) | 2003-08-29 | 2009-04-15 | Takeda Pharmaceutical | Compose de piperazine bicyclique et utilisation de ce dernier |
EP1757290A1 (fr) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Derivés de triazole comme ligands du recepteur de l'hormone de croissance |
PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
ES2604943T3 (es) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos |
WO2009035652A1 (fr) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthèse de benzo[d][1,3]dioxoles et de catéchols deutériés, ainsi que de leurs dérivés |
WO2009078999A1 (fr) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1 |
EP2431035A1 (fr) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Nouveaux dérivés de triazole avec activité de récepteur améliorée et propriétés de biodisponibilité en tant qu'antagonistes de ghréline de récepteurs de secrétagogue d'hormone de croissance |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
WO2013164790A1 (fr) | 2012-05-03 | 2013-11-07 | Novartis Ag | Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline |
EP4232450A1 (fr) | 2020-10-21 | 2023-08-30 | Aligos Therapeutics, Inc. | Composés bicycliques |
WO2022266193A1 (fr) | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Composés bicycliques |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
-
2001
- 2001-04-26 DO DO2001000154A patent/DOP2001000154A/es unknown
- 2001-05-10 CA CA002408036A patent/CA2408036A1/fr not_active Abandoned
- 2001-05-10 JP JP2001585812A patent/JP2003534294A/ja active Pending
- 2001-05-10 MX MXPA02011554A patent/MXPA02011554A/es unknown
- 2001-05-10 WO PCT/IB2001/000815 patent/WO2001089570A2/fr not_active Application Discontinuation
- 2001-05-10 BR BR0111002-0A patent/BR0111002A/pt not_active Application Discontinuation
- 2001-05-10 EP EP01928149A patent/EP1284753A2/fr not_active Withdrawn
- 2001-05-10 AU AU2001255013A patent/AU2001255013A1/en not_active Abandoned
- 2001-05-17 GT GT200100089A patent/GT200100089A/es unknown
- 2001-05-18 US US09/860,786 patent/US20020002137A1/en not_active Abandoned
- 2001-05-23 PE PE2001000472A patent/PE20011262A1/es not_active Application Discontinuation
- 2001-05-24 TN TNTNSN01076A patent/TNSN01076A1/fr unknown
- 2001-05-24 EC EC2001004082A patent/ECSP014082A/es unknown
- 2001-05-24 PA PA20018517701A patent/PA8517701A1/es unknown
- 2001-05-24 SV SV2001000465A patent/SV2001000465A/es unknown
- 2001-05-24 AR ARP010102481A patent/AR028620A1/es not_active Application Discontinuation
- 2001-05-25 UY UY26731A patent/UY26731A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001089570A3 (fr) | 2002-06-20 |
SV2001000465A (es) | 2001-07-03 |
US20020002137A1 (en) | 2002-01-03 |
JP2003534294A (ja) | 2003-11-18 |
GT200100089A (es) | 2002-01-11 |
AR028620A1 (es) | 2003-05-14 |
CA2408036A1 (fr) | 2001-11-29 |
WO2001089570A2 (fr) | 2001-11-29 |
PA8517701A1 (es) | 2002-12-30 |
BR0111002A (pt) | 2003-04-15 |
ECSP014082A (es) | 2002-04-23 |
MXPA02011554A (es) | 2003-04-25 |
UY26731A1 (es) | 2001-12-28 |
DOP2001000154A (es) | 2002-05-15 |
EP1284753A2 (fr) | 2003-02-26 |
PE20011262A1 (es) | 2001-12-11 |
AU2001255013A1 (en) | 2001-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28072A1 (fr) | Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie | |
TNSN99252A1 (fr) | Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant. | |
DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
TNSN01076A1 (fr) | Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant | |
TNSN99253A1 (fr) | Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant. | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
BR0210391A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
TNSN01145A1 (fr) | Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant. | |
ATE165093T1 (de) | Aminoketonderivate | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
HUP0004339A2 (hu) | Nõk kezelési eljárása menopauzát követõen ultra-alacsony dózisú ösztrogénnel | |
TNSN96104A1 (fr) | Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant | |
KR950031060A (ko) | 골다공증 치료용 약제학적 조성물 | |
BG105302A (en) | Means for improving cognition | |
TNSN99001A1 (fr) | Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques | |
TNSN00235A1 (fr) | Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant | |
TNSN98113A1 (fr) | Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline. | |
ATE426402T1 (de) | Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l | |
SE9801495D0 (sv) | Protein formulationa | |
BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
MA27474A1 (fr) | Vaccin |